206 related articles for article (PubMed ID: 35122023)
21. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
Abdel-Wahab O; Dey A
Leukemia; 2013 Jan; 27(1):10-5. PubMed ID: 23147254
[TBL] [Abstract][Full Text] [Related]
22. Deregulation of tumor suppressive ASXL1-PTEN/AKT axis in myeloid malignancies.
Cao L; Xia X; Kong Y; Jia F; Yuan B; Li R; Li Q; Wang Y; Cui M; Dai Z; Zheng H; Christensen J; Zhou Y; Wu X
J Mol Cell Biol; 2020 Sep; 12(9):688-699. PubMed ID: 32236560
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1.
Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor H; Meiners MJ; Cheek MA; Rice W; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ
bioRxiv; 2023 Feb; ():. PubMed ID: 36865140
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic Truncations of ASXL1 Enhance a Motif for BRD4 ET-Domain Binding.
Burgess AE; Kleffmann T; Mace PD
J Mol Biol; 2021 Nov; 433(22):167242. PubMed ID: 34536441
[TBL] [Abstract][Full Text] [Related]
25. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
[TBL] [Abstract][Full Text] [Related]
26. Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.
Guo Y; Yang H; Chen S; Zhang P; Li R; Nimer SD; Harbour JW; Xu M; Yang FC
Leukemia; 2018 Aug; 32(8):1834-1837. PubMed ID: 29743720
[No Abstract] [Full Text] [Related]
27. Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.
Wu X; Bekker-Jensen IH; Christensen J; Rasmussen KD; Sidoli S; Qi Y; Kong Y; Wang X; Cui Y; Xiao Z; Xu G; Williams K; Rappsilber J; Sønderby CK; Winther O; Jensen ON; Helin K
Cell Res; 2015 Nov; 25(11):1205-18. PubMed ID: 26470845
[TBL] [Abstract][Full Text] [Related]
28. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
[TBL] [Abstract][Full Text] [Related]
29. BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition during trophoblast differentiation and invasion.
Perez-Garcia V; Lea G; Lopez-Jimenez P; Okkenhaug H; Burton GJ; Moffett A; Turco MY; Hemberger M
Elife; 2021 Jun; 10():. PubMed ID: 34170818
[TBL] [Abstract][Full Text] [Related]
30. ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers.
Zhang Y; Xie G; Lee JE; Zandian M; Sudarshan D; Estavoyer B; Benz C; Viita T; Asgaritarghi G; Lachance C; Messmer C; Simonetti L; Sinha VK; Lambert JP; Chen YW; Wang SP; Ivarsson Y; Affar EB; Côté J; Ge K; Kutateladze TG
Nat Commun; 2024 Jun; 15(1):4883. PubMed ID: 38849395
[TBL] [Abstract][Full Text] [Related]
31. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
Zhang P; He F; Bai J; Yamamoto S; Chen S; Zhang L; Sheng M; Zhang L; Guo Y; Man N; Yang H; Wang S; Cheng T; Nimer SD; Zhou Y; Xu M; Wang QF; Yang FC
J Clin Invest; 2018 Dec; 128(12):5383-5398. PubMed ID: 30226831
[TBL] [Abstract][Full Text] [Related]
32. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.
Kuznetsov JN; Aguero TH; Owens DA; Kurtenbach S; Field MG; Durante MA; Rodriguez DA; King ML; Harbour JW
Sci Adv; 2019 Sep; 5(9):eaax1738. PubMed ID: 31555735
[TBL] [Abstract][Full Text] [Related]
33. Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder.
Küry S; Ebstein F; Mollé A; Besnard T; Lee MK; Vignard V; Hery T; Nizon M; Mancini GMS; Giltay JC; Cogné B; McWalter K; Deb W; Mor-Shaked H; Li H; Schnur RE; Wentzensen IM; Denommé-Pichon AS; Fourgeux C; Verheijen FW; Faurie E; Schot R; Stevens CA; Smits DJ; Barr E; Sheffer R; Bernstein JA; Stimach CL; Kovitch E; Shashi V; Schoch K; Smith W; van Jaarsveld RH; Hurst ACE; Smith K; Baugh EH; Bohm SG; Vyhnálková E; Ryba L; Delnatte C; Neira J; Bonneau D; Toutain A; Rosenfeld JA; ; Audebert-Bellanger S; Gilbert-Dussardier B; Odent S; Laumonnier F; Berger SI; Smith ACM; Bourdeaut F; Stern MH; Redon R; Krüger E; Margueron R; Bézieau S; Poschmann J; Isidor B
Am J Hum Genet; 2022 Feb; 109(2):361-372. PubMed ID: 35051358
[TBL] [Abstract][Full Text] [Related]
34. The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S; Fujino T; Goyama S; Kitamura T
Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
[TBL] [Abstract][Full Text] [Related]
35. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.
Daou S; Barbour H; Ahmed O; Masclef L; Baril C; Sen Nkwe N; Tchelougou D; Uriarte M; Bonneil E; Ceccarelli D; Mashtalir N; Tanji M; Masson JY; Thibault P; Sicheri F; Yang H; Carbone M; Therrien M; Affar EB
Nat Commun; 2018 Oct; 9(1):4385. PubMed ID: 30349006
[TBL] [Abstract][Full Text] [Related]
36. Structural Basis for the Activation of the Deubiquitinase Calypso by the Polycomb Protein ASX.
De I; Chittock EC; Grötsch H; Miller TCR; McCarthy AA; Müller CW
Structure; 2019 Mar; 27(3):528-536.e4. PubMed ID: 30639226
[TBL] [Abstract][Full Text] [Related]
37. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
38. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Bott M; Brevet M; Taylor BS; Shimizu S; Ito T; Wang L; Creaney J; Lake RA; Zakowski MF; Reva B; Sander C; Delsite R; Powell S; Zhou Q; Shen R; Olshen A; Rusch V; Ladanyi M
Nat Genet; 2011 Jun; 43(7):668-72. PubMed ID: 21642991
[TBL] [Abstract][Full Text] [Related]
39. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
40. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
